P345 The clinical impact of reduced dose prescribing of elexacaftor/tezaxaftor/ivacaftor (ETI) in children with cystic fibrosis
| Autor: | Thomsen, A., Belessis, Y., Bell, R., Chuang, S., Coward, E., Field, P., Jaffe, A., McBride, J., Plush, L., Prentice, B., Strachan, R., Owens, L. |
|---|---|
| Zdroj: | In Journal of Cystic Fibrosis June 2023 22 Supplement 2:S170-S170 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect